64974-45-4

Upstream product

• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 13057-17-5 bromethyl methyl ether 
• 4049-39-2 4-benzyloxy-3-hydroxy-benzaldehyde 
• 107-30-2 chloromethyl methyl ether 

Downstream Products

• 64974-46-5 4-Benzyloxy-3-methoxymethoxy-β-nitrostyrol 
• 64974-47-6 4-Benzyloxy-3-methoxymethoxyphenethylamin 
• 64974-59-0 3-{[2-(4-Hydroxy-3-methoxy-phenyl)-ethyl]-methyl-amino}-6-methoxy-indan-5-ol 
• 64974-58-9 2-Benzyloxy-5-{2-[(6-benzyloxy-5-methoxy-indan-1-yl)-methyl-amino]-ethyl}-phenol 
• 64974-49-8 N-(4-Benzyloxy-3-hydroxyphenethyl)-4-benzyloxy-3-methoxy-phenylpropionamid 
• 64974-56-7 (6-Benzyloxy-5-methoxy-indan-1-yl)-[2-(4-benzyloxy-3-methoxy-phenyl)-ethyl]-methyl-amine 
• 64974-50-1 N-(3-Acetoxy-4-benzyloxyphenethyl)-4-benzyloxy-3-methoxy-phenylpropionamid 
• 64974-57-8 1-amino-6-benzyloxy-5-methoxyindan 
• 64974-48-7 N-(4-Benzyloxy-3-methoxymethoxyphenethyl)-4-benzyloxy-3-methoxy-phenylpropionamid 
• 1599469-73-4 C₆₉H₆₂O₁₄ 
• 1599469-72-3 C₃₅H₃₀O₈ 
• 1599469-71-2 C₃₇H₃₄O₉ 
• 1599469-70-1 C₂₄H₂₀O₆ 
• 1448000-75-6 4-(4-methoxy-3-(4-(5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl)phenoxy)phenethyl)-2-(methoxymethoxy)phenyl trifluoromethanesulfonate 

Relevant academic research and scientific papers

Fluoroethoxylanin as well as preparation method and application thereof

The invention relates to fluoroethoxylanin as well as a preparation method and application thereof. The preparation method comprises the following steps: firstly, 3,4 -hydroxybenzaldehyde and benzyl chloride serve as raw materials, and 3 -hydroxy -4 -benzyloxybenzaldehyde is prepared. The product is reacted with bromomethyl methyl ether, and the product is sequentially subjected Wittig reaction, reduction reaction and alkylation reaction, and the obtained product is reacted with p-toluenesulfonic acid chloride to obtain fifth intermediate. Finally fifth intermediate and complexing agent K are added. 2.2.2 . Reaction of potassium fluoride and acidification of the product gave the above fluoroethoxylanolin. Compared with the prior art, the fluoroethoxylanin prepared by the invention can reflect the distribution of the tracer in the local tissue of the organism, thereby visualizing the tumors, and providing the metabolic information targeting metabolic pathway types and.

NOVEL FLAVONOID COMPOUNDS AND USES THEREOF

The present disclosure provides a compound of the following formula, racemates, enantiomers, prodrugs and salts thereof: Formula (I). Also provided is the use of these compounds for the treatment of ischemia and reperfusion injuries. Further applications include the treatment of diseases caused by cell apoptosis and / or cell necrosis.

Total synthesis of riccardin C and (±)-cavicularin via Pd-catalyzed Ar-Ar cross couplings

Riccardin C, a specific LXRα agonist, is a representative macrocyclic bisbibenzyl-type natural product. As part of our synthetic studies on macrocyclic bisbibenzyls, the synthesis of riccardin C and its analog cavicularin was examined. The total synthesis

Enantioselective synthesis of orthogonally protected (2R,3R)-(-)- epicatechin derivatives, key intermediates in the de novo chemical synthesis of (-)-epicatechin glucuronides and sulfates

Ten orthogonally protected (-)-epicatechin and 3′- or 4′-O-methyl-(-)-epicatechin derivatives were prepared in a regiospecific and enantioselective manner. For each orthogonally protected (-)-epicatechin derivative, one specific phenolic hydroxyl was protected with a methoxymethyl (MOM) or p-methoxybenyzl (PMB) group and the remainder were protected as benzyl ethers. These uniquely protected (-)-epicatechin derivatives were designed to facilitate the regiospecific installation of a glucuronic acid or sulfate unit onto (-)-epicatechin after selective removal of the MOM or PMB protecting group to provide authentic standards of (-)-epicatechin glucuronides and sulfates.

Synthesis, biological evaluation, and structure-activity relationship study of novel cytotoxic aza-caffeic acid derivatives

Three series of aza-caffeic acid derivatives with different linkers were designed and synthesized. Each of the synthesized derivatives was then used in cytotoxicity screening on either 8 or 12 human cancer cell lines. The structure-activity relationships on three structural regions A, B, and C are analyzed in detail, indicating that a nine bond linker B, containing a piperazine unit, is the most favorable linker leading to the generation of molecules with potent cytotoxicities. Compound (E)-1-(4-(3,4-dichlorobenzyl) piperazin-1-yl)-3-(4-(4-ethoxybenzyloxy)-3,5-dimethoxyphenyl)prop-2-en-1-one (80) exhibited the most significant and selective cytotoxicity to KB, BEL7404, K562, and Eca109 cell lines, with IC50 values of 0.2, 2.0, 1.7, and 1.1 μM, respectively, stronger than that seen for caffeic acid phenethyl ester (CAPE) and cisplatin (CDDP). Flow cytometric and western blot analysis indicate that compound 80 plays a role in mitochondria-dependent apoptosis activity by suppressing K562 cell proliferation in a concentration- and time-dependent manner.

NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION

Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease